Cellular senescence: a double-edged sword in cancer therapy
Frontiers in Oncology · 12.09.2023 · 13
DOI: 10.3389/fonc.2023.1189015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 12.09.2023. Verfasst von Shuai Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei …. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Over the past few decades, cellular senescence has been identified in cancer patients undergoing chemotherapy and radiotherapy. Senescent cells are generally characterized by permanent cell cycle arrest as a response to endogenous and exogenous stresses. In addition to exiting the cell cycle process, cellular senescence also triggers profound phenotypic changes such as senescence-associated secretory phenotype (SASP), autophagy modulation, or metabolic reprograming. Consequently, cellular senescence is often considered as a tumor-suppressive mechanism that permanently arrests cells at risk of malignant transformation. However, accumulating evidence shows that therapy-induced senescence can promote epithelial-mesenchymal transition and tumorigenesis in neighboring cells, as well as re-entry into the cell cycle and activation of cancer stem cells, thereby promoting cancer cell survival. Therefore, it is particularly important to rapidly eliminate therapy-induced senescent cells in patients with cancer. Here we review the hallmarks of cellular senescence and the relationship between cellular senescence and cancer. We also discuss several pathways to induce senescence in tumor therapy, as well as strategies to eliminate senescent cells after cancer treatment. We believe that exploiting the intersection between cellular senescence and tumor cells is an important means to defeat tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, Wuhan, China.
- Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, China.
- Membrane Protein Disease Research Group, Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Zitieren
APA
Xiao, S., Qin, D., Hou, X., Tian, L., Yu, Y., Zhang, R., Lyu, H., Guo, D., Chen, X. Z., Zhou, C., & Tang, J. (2023). Cellular senescence: a double-edged sword in cancer therapy. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1189015
Vancouver
Xiao S, Qin D, Hou X, Tian L, Yu Y, Zhang R, et al. Cellular senescence: a double-edged sword in cancer therapy. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1189015
BibTeX
@article{Xiao2023,
author = {Xiao, Shuai and Qin, Dongmin and Hou, Xueyang and Tian, Lingli and Yu, Yeping and Zhang, Rui and Lyu, Hao and Guo, Dong and Chen, Xing-Zhen and Zhou, Cefan and Tang, Jingfeng},
title = {Cellular senescence: a double-edged sword in cancer therapy},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1189015}
}
EUVIMED